Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.
ASJC Scopus subject areas
- Pharmacology (medical)